Glenmede Trust’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.14M | Buy |
11,652
+1,733
| +17% | +$319K | 0.01% | 563 |
|
|
2025
Q4 | $1.75M | Buy |
+9,919
| New | +$1.62M | 0.01% | 589 |
|
|
2025
Q1 | $9.79M | Sell |
71,547
-17,476
| -20% | -$2.5M | 0.05% | 358 |
|
|
2024
Q4 | $13.6M | Buy |
89,023
+11,722
| +15% | +$1.98M | 0.07% | 304 |
|
|
2024
Q3 | $15M | Buy |
77,301
+66,583
| +621% | +$13.9M | 0.07% | 283 |
|
|
2024
Q2 | $2.48M | Sell |
10,718
-1,711
| -14% | -$372K | 0.01% | 517 |
|
|
2024
Q1 | $2.68M | Sell |
12,429
-1,095
| -8% | -$256K | 0.01% | 522 |
|
|
2023
Q4 | $3.5M | Sell |
13,524
-14,740
| -52% | -$3.62M | 0.02% | 467 |
|
|
2023
Q3 | $7.26M | Sell |
28,264
-58,328
| -67% | -$15.6M | 0.04% | 374 |
|
|
2023
Q2 | $24.1M | Sell |
86,592
-109
| -0.1% | -$32.4K | 0.14% | 167 |
|
|
2023
Q1 | $24.1M | Sell |
86,701
-2,573
| -3% | -$712K | 0.14% | 167 |
|
|
2022
Q4 | $24.7M | Buy |
89,274
+12,607
| +16% | +$3.56M | 0.15% | 161 |
|
|
2022
Q3 | $20.5M | Sell |
76,667
-32,762
| -30% | -$6.96M | 0.13% | 180 |
|
|
2022
Q2 | $22.3M | Sell |
109,429
-8,615
| -7% | -$1.76M | 0.13% | 175 |
|
|
2022
Q1 | $24.9M | Sell |
118,044
-6,573
| -5% | -$1.43M | 0.12% | 195 |
|
|
2021
Q4 | $29.9M | Sell |
124,617
-21,842
| -15% | -$5.62M | 0.14% | 166 |
|
|
2021
Q3 | $41.4M | Buy |
146,459
+385
| +0.3% | +$126K | 0.21% | 116 |
|
|
2021
Q2 | $50.6M | Sell |
146,074
-51,178
| -26% | -$15.5M | 0.26% | 100 |
|
|
2021
Q1 | $55.2M | Sell |
197,252
-197,559
| -50% | -$53.3M | 0.3% | 88 |
|
|
2020
Q4 | $96.7M | Sell |
394,811
-10,788
| -3% | -$2.78M | 0.53% | 42 |
|
|
2020
Q3 | $115M | Sell |
405,599
-40,684
| -9% | -$11.3M | 0.69% | 28 |
|
|
2020
Q2 | $119M | Sell |
446,283
-87,239
| -16% | -$26.2M | 0.73% | 27 |
|
|
2020
Q1 | $158M | Hold |
533,522
| – | – | 0.72% | 28 |
|
|
2019
Q4 | $158M | Sell |
533,522
-95,565
| -15% | -$26.5M | 0.72% | 28 |
|
|
2019
Q3 | $146K | Sell |
629,087
-6,392
| -1% | -$1.49M | 0.67% | 28 |
|
|
2019
Q2 | $149K | Buy |
635,479
+194,018
| +44% | +$44.8M | 0.65% | 28 |
|
|
2019
Q1 | $104K | Buy |
441,461
+5,282
| +1% | +$1.66M | 0.47% | 48 |
|
|
2018
Q4 | $131K | Buy |
436,179
+27,590
| +7% | +$8.8M | 0.64% | 26 |
|
|
2018
Q3 | $144M | Sell |
408,589
-13,095
| -3% | -$4.51M | 0.58% | 30 |
|
|
2018
Q2 | $122M | Buy |
421,684
+94,748
| +29% | +$26.6M | 0.54% | 34 |
|
|
2018
Q1 | $104M | Hold |
326,936
| – | – | 0.43% | 56 |
|
|
2017
Q4 | $104M | Sell |
326,936
-12,917
| -4% | -$4.14M | 0.43% | 56 |
|
|
2017
Q3 | $106M | Sell |
339,853
-154,595
| -31% | -$45.8M | 0.47% | 51 |
|
|
2017
Q2 | $135M | Hold |
494,448
| – | – | 0.65% | 19 |
|
|
2017
Q1 | $135M | Buy |
494,448
+80,817
| +20% | +$22.9M | 0.65% | 19 |
|
|
2016
Q4 | $117M | Buy |
413,631
+11,957
| +3% | +$3.54M | 0.64% | 20 |
|
|
2016
Q3 | $126M | Buy |
401,674
+91,281
| +29% | +$27M | 0.71% | 18 |
|
|
2016
Q2 | $75.1M | Sell |
310,393
-25,815
| -8% | -$6.8M | 0.46% | 41 |
|
|
2016
Q1 | $87.5M | Buy |
336,208
+78,544
| +30% | +$20.7M | 0.57% | 29 |
|
|
2015
Q4 | $78.9M | Buy |
257,664
+229,426
| +812% | +$65.9M | 0.54% | 34 |
|
|
2015
Q3 | $8.24M | Sell |
28,238
-42,581
| -60% | -$14.1M | 0.06% | 357 |
|
|
2015
Q2 | $28.6M | Buy |
70,819
+37,928
| +115% | +$15.2M | 0.21% | 155 |
|
|
2015
Q1 | $13.9M | Sell |
32,891
-1,176
| -3% | -$464K | 0.1% | 305 |
|
|
2014
Q4 | $11.6M | Buy |
34,067
+3,503
| +11% | +$1.13M | 0.09% | 324 |
|
|
2014
Q3 | $10.1M | Buy |
30,564
+149
| +0.5% | +$49.1K | 0.09% | 307 |
|
|
2014
Q2 | $9.59M | Sell |
30,415
-11
| -0% | -$3.31K | 0.09% | 313 |
|
|
2014
Q1 | $9.3M | Sell |
30,426
-5,511
| -15% | -$1.75M | 0.09% | 307 |
|
|
2013
Q4 | $10M | Sell |
35,937
-233
| -0.6% | -$60.3K | 0.1% | 269 |
|
|
2013
Q3 | $8.71M | Sell |
36,170
-677
| -2% | -$152K | 0.1% | 256 |
|
|
2013
Q2 | $7.93M | Buy |
+36,847
| New | +$7.87M | 0.1% | 229 |
|
Other funds holding BIIB
VCM
VPM
Glenmede Trust's BIIB Position: Q1 2026 in Review
Glenmede Trust increased its Biogen (BIIB) stake by 17% in Q1 2026, buying an estimated $319K and bringing the position to 11,652 shares worth $2.14M. The position accounts for 0.01% of the portfolio, ranked #563.
Glenmede Trust first reported a position in BIIB in Q2 2013 and has held it in 50 quarters since. The position peaked at $158M in Q1 2020. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Glenmede Trust held 11,652 shares of Biogen worth $2.14M as of Q1 2026.
- Glenmede Trust bought 1,733 Biogen shares in Q1 2026, an estimated $319K.
- Biogen made up 0.01% of Glenmede Trust's portfolio in Q1 2026, its #563 holding.
- Glenmede Trust first reported a position in Biogen in Q2 2013 and has held it in 50 quarters since.
- Glenmede Trust's Biogen position peaked at $158M in Q1 2020.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.